The Serum Institute of India, the world's biggest vaccine maker, has applied to local authorities to conduct a small domestic trial of American vaccine developer Novavax's COVID-19 jab, which was found to be 89.3 per cent effective in a UK trial. It was also found to be highly effective against a variant first identified in the UK. But the positive Phase 3 clinical trial data was partly offset by other results that showed it offered significantly less protection against a highly transmissible variant of the coronavirus first identified in South Africa, which is spreading rapidly around the world.

NDTV is one of the leaders in the production and broadcasting of un-biased and comprehensive news and entertainment programmes in India and abroad. NDTV delivers reliable information across all platforms: TV, Internet and Mobile.

Subscribe for more videos: [ Ссылка ]
Like us on Facebook: [ Ссылка ]
Follow us on Twitter: [ Ссылка ]
Download the NDTV Apps: [ Ссылка ]
Watch more videos: [ Ссылка ]

свернуть